Skip to content

Study, 2023

Are testosterone and prolactin levels different in women with PMDD?

Yes. Women with PMDD and high depression scores had lower levels of a protein called β-Arrestin1 alongside higher testosterone and prolactin levels in their blood.

Early or limited evidence 25 non-pregnant women aged 18-42 not on antidepressants

What they did

25 non-pregnant women aged 18-42 who were not on antidepressants were studied during the late luteal phase (the week before the period). Blood tests measured a protein called β-Arrestin1 in white blood cells and testosterone and prolactin levels. Researchers looked at whether these hormones related to depression severity.

What they found

Women with depression scores above 19 had lower β-Arrestin1 protein levels and higher testosterone and prolactin levels in their blood.

What it means for you

The findings suggest that changes in testosterone and prolactin during the luteal phase might affect a protein involved in PMDD and depression. Understanding this could help find new drug targets for PMDD treatment. The study is very small and looked at only one time point in the cycle.

25

women studied

18-42

age range

19

depression score cutoff

About the study

Original title
Testosterone and Prolactin Perturbations Possibly Associated with Reduced Levels of β-Arrestin1 in Mononuclear Leukocytes of Women with Premenstrual Dysphoric Disorder
Authors
Nayyar S, Archibong A, Nayyar T
Journal
International journal of molecular sciences
Year
2023
Study design
Study
Participants
25
What was tested
None - hormonal measurement
Open access
Yes
Original abstract

Previously, we reported that a reduction in β-Arrestin1 protein levels in peripheral blood mononuclear leukocytes (PBMC) significantly correlated with the severity of depression symptoms in women with premenstrual dysphoric disorder (PMDD). This study aimed to determine whether the reduced premenstrual β-Arrestin1 protein levels were associated with changes in the regulator for late luteal phase progesterone secretion. The study participants ( n = 25) were non-pregnant women between 18 and 42 years of age not taking any antidepressants or receiving therapy and experiencing the luteal phase of menstruation. ELISA determined the β-Arrestin1 protein in PBMC; testosterone and prolactin levels from the plasma were determined by radioimmunoassay. Reduced levels of β-Arrestin1 protein in women with Hamilton Rating Scale for Depression (HAM-D) scores above 19 were observed alongside significantly higher plasma testosterone and prolactin concentrations. Understanding the mechanism underlying the initiation of PMDD will allow for identification of a key perturbed metabolic enzyme that can serve as a target for drug development to ensure the alleviation of PMDD, which has been suggested earlier as a risk factor for developing major depressive disorders.

Reproduced under CC-BY.

Topics